



Flexion Therapeutics, Inc.
Investor Relations Department
10 Mall Road
Suite 301
Burlington, MA 01803
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: FLXN

| | |
|---------------|--|
| Last Trade: | 24.73 |
| Trade Time: | 4:00 PM ET Apr 20, 2018 |
| Change: | -0.36 ▼ (-1.435%) |
| Day Range | 24.37 - 25.14 |
| 52-Week Range | 16.51 - 32.25 |
| Volume | 754,696 |


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Flexion is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Apr 18, 2018

[Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® \(triamcinolone acetonide extended-release injectable suspension\) in the Journal of Bone and Joint Surgery](#)

Apr 6, 2018

[Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Mar 19, 2018

[Flexion Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference](#)

Mar 8, 2018

[Flexion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results](#)

Mar 7, 2018

[Flexion Therapeutics to Present at the Cowen 38th Annual Health Care Conference](#)

Financials [\[View all \]](#)

[Fourth Quarter Financial Results](#)

Mar 8, 2018

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 6, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)